Rhythm Biosciences Limited (ASX:RHY)

Market Cap	29.05M
Revenue (ttm)	3.19M
Net Income (ttm)	-3.83M
Shares Out	322.74M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	466,121
Average Volume	501,727
Open	0.0900
Previous Close	0.0910
Day's Range	0.0890 - 0.0920
52-Week Range	0.0470 - 0.2100
Beta	2.10
RSI	51.04
Earnings Date	Aug 29, 2025

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. The company develops ColoSTAT, a blood test for the early detection of colorectal cancer. It also acquired Genetype to expand product offerings. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RHY

Financial Performance

In 2025, Rhythm Biosciences's revenue was 3.19 million, an increase of 88.85% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.